Business Overview: Opus Genetics, Inc. (Nasdaq: IRD)

---

Executive Summary

Opus Genetics, Inc. (formerly Ocuphire Pharma, which it became after a 2024 reverse merger combining Ocuphire with the private gene-therapy company Opus Genetics) is a clinical-stage ophthalmology biotechnology company headquartered in Durham, North Carolina. The company pursues two parallel lines of business: a pipeline of AAV-based gene therapies for inherited retinal diseases (IRDs) — rare, often blinding genetic eye conditions with no approved treatments — and a portfolio of small-molecule ophthalmic drugs, the most advanced of which (phentolamine ophthalmic solution) is already FDA-approved and commercially marketed by a partner.

Opus matters because it sits at the intersection of two distinct value-creation stories: a de-risked, partnered small-molecule franchise generating real royalty and milestone cash today, and a genuinely novel gene-therapy pipeline targeting diseases that currently have zero approved treatment options — a true unmet-need, orphan-drug setup. A $155 million non-dilutive financing from Oberland Capital (announced in 2026) is intended to fund the gene-therapy pipeline through pivotal trials for its two lead programs.

---

1. Core Business Model & How They Work

Opus Genetics operates a dual-engine biotech model: a capital-light, partnered small-molecule business funding a capital-intensive, high-risk/high-reward gene-therapy pipeline.

[ Gene Therapy: AAV Vector Design ] ➡️ [ Preclinical/Phase 1-2 (often at academic partners, e.g. UPenn) ] ➡️ [ Pivotal Trial ] ➡️ [ BLA Filing ] ➡️ [ Approval & Commercialization ]

[ Small Molecule: Phentolamine Ophthalmic Solution ] ➡️ [ Partnered Commercialization (Viatris) ] ➡️ [ Upfront + Milestones + Royalties to Opus ]

Key Operational Drivers

1. Partnered commercialization for small molecules: Opus has no commercial sales force of its own. Its lead approved asset, RYZUMVI® (phentolamine ophthalmic solution 0.75%, for pharmacologically induced mydriasis reversal), is commercialized entirely by Viatris, which pays Opus an upfront fee ($35 million at signing), milestones (up to $130 million total, with $10 million triggered by the mydriasis approval), and tiered royalties.
2. Academic and asset-acquisition sourcing for gene therapy: Rather than discovering every gene-therapy candidate internally, Opus licenses programs from academic labs (e.g., the University of Pennsylvania for OPGx-LCA5 and OPGx-RDH12) and acquired assets from Iveric Bio (BEST1 and RHO programs), reducing early discovery risk and cost.
3. Orphan/rare-disease regulatory pathway: Because inherited retinal diseases are individually rare, Opus's lead program has received RMAT, orphan drug, and rare pediatric disease designations — regulatory tools that can accelerate review and provide market exclusivity and priority-review voucher value.
4. Milestone-funded, tranche-based non-dilutive capital: The 2026 Oberland Capital financing (up to $155 million, with an initial $35 million payment plus a $5 million equity investment, and additional tranches tied to clinical milestones) exemplifies a financing strategy built to avoid heavy equity dilution while funding a multi-year gene-therapy pivotal program.

---

2. Business Segments

Opus does not report distinct financial segments, but its pipeline splits cleanly into two therapeutic modalities with very different risk/reward and commercialization profiles.

                     ┌───────────────────────────────┐
                     │        Opus Genetics, Inc.      │
                     └────────────────┬────────────────┘
                                       │
          ┌────────────────────────────┼────────────────────────────┐
          ▼                                                         ▼
┌──────────────────────────┐                            ┌──────────────────────────┐
│   Gene Therapy Pipeline   │                            │  Small-Molecule Pipeline  │
│ (AAV-based, IRDs)         │                            │  (Phentolamine PS, APX3330)│
└─────────────┬──────────────┘                            └─────────────┬──────────────┘
              │                                                         │
   ┌──────────┴──────────┬───────────────┐              ┌───────────────┴───────────────┐
   │   OPGx-LCA5 (lead)   │  OPGx-BEST1    │              │  RYZUMVI (mydriasis, approved) │
   │   Phase 1/2/3         │  Phase 1/2     │              │  Presbyopia (VEGA, w/ Viatris)  │
   │                       │                │              │  Dim-light disturbance (LYNX)  │
   │  Preclinical: RHO,    │                │              │  APX3330 (diabetic retinopathy,│
   │  RDH12, MERTK,        │                │              │  seeking partner)              │
   │  NMNAT1, CNGB1        │                │              │                                 │
   └───────────────────────┴────────────────┘              └─────────────────────────────────┘

Gene Therapy Pipeline (the company's long-term value driver)

The lead program, OPGx-LCA5 (for LCA5-related Leber congenital amaurosis), showed no dose-limiting toxicities in an academic Phase 1/2 trial at UPenn; Opus plans a pivotal single-arm study (as few as 8 participants) with dosing expected in the second half of 2026. OPGx-BEST1 (for BEST1-related bestrophinopathies, including Best vitelliform macular dystrophy) began dosing in its Phase 1/2 BIRD-1 trial in November 2025. Five additional preclinical programs (OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, OPGx-CNGB1) round out the pipeline, with RDH12 and MERTK both expected to enter clinical testing by the end of 2026.

Small-Molecule Pipeline (the near-term cash engine)

Phentolamine ophthalmic solution 0.75% is already FDA-approved and commercially launched (by Viatris, April 2024) under the brand RYZUMVI for reversing pharmacologically induced mydriasis. The same molecule is in late-stage development for two additional indications: presbyopia (VEGA-3 met its primary endpoint in June 2025; Viatris filed a supplemental NDA with an FDA PDUFA date of October 17, 2026) and dim-light disturbances after keratorefractive surgery (LYNX-2 met its primary endpoint; LYNX-3 topline data expected first half of 2026). APX3330, an oral candidate for diabetic retinopathy, missed its primary endpoint in a Phase 2b trial, and Opus is now seeking a strategic partner rather than advancing it alone.

---

3. Product Portfolio

---

4. Competitive Landscape

Opus's competitive exposure differs sharply between its two pipelines.

Gene Therapy for Inherited Retinal Disease

• Opus describes no known direct competitors for its LCA5 or BEST1 programs — a function of how narrowly defined (by specific causative gene) inherited retinal disease indications are.
• RDH12 faces an investigator-initiated trial in China and a competing program from MeiraGTX.
• RHO (rhodopsin-related retinitis pigmentosa) faces a competing program from Octant Bio.
• This is a market structure where competition is sparse but so is commercial precedent — there is no large approved IRD gene-therapy franchise yet to benchmark against, unlike, say, oncology.

Presbyopia (Phentolamine PS / VEGA)

• Competitors include Lenz Therapeutics, AbbVie's VUITY, and TenPoint Therapeutics' YUVEZZI — all targeting the same pharmacologic presbyopia category with pupil-modulating eye drops.

Mydriasis Reversal (RYZUMVI)

• Sandoz has filed an ANDA with a Paragraph IV challenge against six RYZUMVI patents; Opus and Viatris sued in March 2025, with trial set for January 2027 — a direct test of how durable the approved product's patent protection really is.

Diabetic Retinopathy (APX3330, deprioritized)

• The entrenched standard of care is anti-VEGF therapy (Vabysmo, Lucentis, Eylea) plus laser photocoagulation and vitrectomy — a crowded, well-funded category that an oral small molecule like APX3330 would have had to displace or supplement.

---

5. Strategic Strengths & Risks

Strengths

• A real, de-risked revenue bridge: Unlike most clinical-stage gene-therapy companies, Opus already has an FDA-approved, commercially launched product (RYZUMVI) generating milestone and royalty cash through a well-capitalized partner (Viatris), with two more potential label expansions (VEGA, LYNX) pending.
• First-mover position in ultra-rare gene therapy niches: With no known direct competitors in its two lead gene-therapy indications (LCA5, BEST1), Opus has a real shot at being first to market in diseases that currently have zero approved treatments.
• Non-dilutive funding runway: The 2026 Oberland Capital financing (up to $155 million) extends the company's cash runway into 2029 without requiring equity issuance tied to it, materially reducing near-term dilution risk relative to a typical clinical-stage biotech.
• Regulatory tailwinds: RMAT, orphan drug, and rare pediatric disease designations for OPGx-LCA5 can shorten review timelines and add commercial exclusivity value.

Risks

• Binary clinical trial risk: Gene therapy trials are small (as few as 8 participants in the planned OPGx-LCA5 pivotal study), meaning a single adverse event or ambiguous efficacy signal can meaningfully set back the program; APX3330's Phase 2b miss is a concrete example of pipeline risk materializing.
• Patent challenge to the core approved asset: Sandoz's Paragraph IV challenge to RYZUMVI's patents, with trial set for January 2027, creates real uncertainty about how long the company's one approved, revenue-generating product retains exclusivity.
• Dependence on partners for commercialization and some discovery: Opus has no in-house sales force and relies on Viatris for RYZUMVI/VEGA/LYNX commercialization, and on academic/licensed assets (UPenn, Iveric) for a meaningful share of its gene-therapy pipeline — concentrating execution risk in a small number of external relationships.
• Still a net-loss clinical-stage company: Despite real partnered revenue, Opus posted a net loss of roughly $49.6 million in 2025, with R&D expense of $30.8 million and G&A of $22.0 million — the gene-therapy pipeline remains years from potential approval and cash-flow breakeven.

---

6. Financial Overview

---

7. Summary Conclusion

Opus Genetics is a two-speed biotech: a partnered, already-approved small-molecule franchise (RYZUMVI, with presbyopia and dim-light-disturbance label expansions pending) throwing off real milestone and royalty cash today, bolted onto a genuinely novel, largely uncontested gene-therapy pipeline targeting inherited retinal diseases that currently have no approved treatment at all. The 2026 Oberland Capital financing materially de-risks the near-term funding picture for the gene-therapy pivotal trials, and the rare-disease regulatory designations attached to the lead OPGx-LCA5 program are a real structural advantage. But the company remains a net-loss, clinical-stage business whose ultimate value depends on binary trial outcomes in very small patient populations, and its one proven, revenue-generating asset (RYZUMVI) now faces a direct patent challenge from Sandoz — meaning the next 18-24 months of gene-therapy trial readouts and patent litigation will likely determine far more about Opus's future than its current financials do.